Maryland Oncology Hematology Adds Experienced Gynecologic Surgical Oncologist James Barter, MD, FACOG to White Oak Cancer Center

Dr. Barter is an accomplished surgeon and clinical researcher who will provide state-of-the-art treatments and minimally invasive surgical options to patients in the region.

Maryland, 3/15.2022 – Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, has added Dr. James Barter, MD, FACOG to their gynecologic oncology and surgical team at White Oak Cancer Center. Dr. Barter is experienced in minimally invasive surgeries and has performed more than 1,700 robotic surgeries and procedures.

Dr. Barter joins Maryland Oncology Hematology at The White Oak Cancer Center. Dr. Barters’ current interests include surgery using the Da Vincia surgical robot to assist in gynecologic surgery. He is ranked in the top 15 users worldwide for robotic gynecologic and gynecologic oncology procedures and has lectured both locally and internationally on the topic. Along with his extensive research with Dr. David Min and the HCSS research division, Dr. Barter has activated and overseen clinical trials with over 1,300 patients entered in protocols since 2006.

“I’m looking forward to partnering with Maryland Oncology Hematology to provide leading-edge, researchbased, and patient-centered care to the community,” said Dr. Barter, a gynecologic surgeon at White Oak Cancer Center. “With a firm understanding of the latest treatment advances and surgical techniques, I hope to bring patients new cancer care options.”

Dr. Barter is recognized as one of the country’s leading gynecologists by Good Housekeeping, perennially as one of the Top Doctors in the Washington, D.C. area, as well as one of only two gynecologic oncologists noted as top doctors in Northern Virginia. He is currently a clinical professor at George Washington University and director of gynecologic oncology research at Holy Cross Hospital. He received his medical degree from the University of Virginia and completed two years of internal medicine and four years of obstetrics and gynecology at Duke University Medical Center, followed by a fellowship in gynecologic oncology at the University of Alabama Medical Center. He was at Lombardi Cancer Center/ Georgetown University Medical Center for 16 years, rising to the rank of professor.

His four-year interest in the development of a serum blood test for ovarian cancer detection will soon culminate in published research involving serum proteomics. In conjunction with Holy Cross, Dr. Barter continues his interest in protocols dealing with novel approaches for ovarian cancer treatment, having received research grants.

“We’re thrilled to have Dr. Barter join our team of talented surgeons at Maryland Oncology Hematology” said Kashif Firozvi, MD, Director at White Oak Cancer Center. “His background in research and clinical trials, as well as his impressive experience in both gynecologic oncology and surgery will be of great benefits to the local community.”

White Oak Cancer Center is located at 11886 Healing Way Suite 101, Silver Spring, MD, 20904. To learn more or to schedule an appointment, visit MarylandOncology.com or call 301.343.3892.

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,400 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

 

To be distributed to local media:

Practice: Maryland Oncology Hematology

Contact: Mark Lamplugh

Phone : 561-762-9729

Email : mark.lamplugh@usoncology.com

Facebooktwitterlinkedinmail

What is a Cancer Clinical Trial?

When you or a loved one is diagnosed with cancer, learning about what a clinical trial is and deciding what treatment to pursue can be daunting. When you’ve exhausted the available cancer treatment options, whether through radiation oncology, hematology-oncology or some other specialty, it can be scary to think that’s there isn’t a treatment option left. Fortunately, clinical trials can provide hope and alternative treatment options for cancer patients who need them.

What Are Cancer Clinical Trials?

Clinical trials are the last phase in getting regulatory approval for new pharmaceutical medications, devices or protocols. After months or years of research and testing in the lab and, in many cases, on animals, human testing is needed to ensure safety and effectiveness. Clinical trials are conducted at many research institutions, hospitals, and community based clinics (or practices) around the world.

Why Clinical Trials Exist

Clinical trials exist to get new treatment options to patients. For instance, a clinical trial about investigational breast cancer treatments may lead to more successful outcomes for breast cancer surgeons and their patients. In addition to measuring safety, clinical trials can determine if a new therapy works, makes no difference or further impairs patients.

Who Benefits From Clinical Trials

Many people benefit from clinical trials. First, patients involved in clinical trials receive life-saving treatment earlier than it would normally be available. This is ideal for cancer patients who haven’t responded to approved therapies. For patients who cannot afford treatment, involvement in a clinical trial is sometimes at no cost to the patient. Second, researchers, doctors, and pharmaceutical manufacturers benefit by having humans to test their experimental cancer treatments on.

Third, no matter what the outcome of the trial, future cancer patients strongly benefit from clinical trials. If a new medication or treatment proves to be successful, future patients will be able to use it as a regular part of their treatment. If the clinical trial fails, future patients will not be exposed, and researchers can identify drugs that could provide better outcomes in the future.

How Clinical Trials Are Conducted

Human clinical trials are conducted in three different phases. Depending on the actual trial, there might be more phases. The first phase involves a small number of patients, and the primary concern is the safety or side effects of the treatment. Clinical trials do not aim to hurt people, so at first, the first phase stays small so researchers can closely monitor what happens. This phase happens after a lot of research has already been conducted in the lab, so there is less chance of a foreseeable adverse reaction.

The second phase also uses a small group of people. Instead of just focusing on safety, this phase examines how well the proposed treatment works. If the results still look promising, a third phase involves a larger number of people with less stringent guidelines. For example, if an earlier phase only allowed geriatric patients to be involved, this phase might expand the parameters to evaluate possible side effects and compare alternative treatments to see which is better for whom.

How to Participate in a Clinical Trial

For patients interested in participating in a clinical trial, the first step is to try conventional cancer treatment options, if possible. Many trials will ask what you’ve already tried. Next, patients need to find clinical trials through online databases, their oncologist or a local cancer center to see who’s eligible to participate.

Maryland Oncology Hematology currently has active clinical trials for breast cancer, lung cancer, Chronic Lymphocytic Leukemia (CLL), metastatic malignancies, multiple myeloma, supportive therapies and gastric cancers. These include clinical trials for many different stages of these cancers. To participate, you should ask your oncologist or contact Maryland Oncology Hematology directly.

Facebooktwitterlinkedinmail

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology